Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Insmed Inc (INSM)

Insmed Inc (INSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Insmed Inc 700 US Highway 202/206 Bridgewater NJ 08807 USA

P: 908-977-9900

Description:

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

Key Statistics

Overview:

Market Capitalization, $K 3,410,777
Shares Outstanding, K 101,481
Annual Sales, $ 136,470 K
Annual Net Income, $ -254,340 K
Last Quarter Sales, $ 42,500 K
Last Quarter Net Income, $ -61,850 K
60-Month Beta 2.65
% of Insider Shareholders 4.63%
Float, K 96,782
% Float 95.37%

Growth:

1-Year Return 84.67%
3-Year Return 7.69%
5-Year Return 72.89%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -63.59%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.64 on 08/06/20
Next Earnings Date 11/04/20
Earnings Per Share ttm -2.65
EPS Growth vs. Prev Qtr 13.51%
EPS Growth vs. Prev Year 20.99%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-10 on 03/03/11

INSM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -4.34
Price/Earnings to Growth N/A
Return-on-Equity % -82.15%
Return-on-Assets % -31.54%
Profit Margin % -186.37
Net Margin % -565.27
Debt/Equity 1.74
Price/Sales 24.88
Price/Cash Flow N/A
Price/Book 8.34
Book Value/Share 4.01
Interest Coverage -8.15
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar